The effects of chronic levodopa treatment on pre- and postsynaptic markers of dopaminergic function in striatum of Parkinsonian monkeys

Movement Disorders

Volumn 12, Issue 2, 1997, Pages 148-158

  Rioux, Lise ^a   Frohna, Paul A ^a   Joyce, Jeffrey N ^a,c   Schneider, Jay S ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c SUN HEALTH RESEARCH INSTITUTE   (United States)

Author keywords

1 Methyl 4 phenyl 1,2,3,6 tetrahydropyridine; Basal ganglia; Dopamine receptors; Dopamine uptake sites; Parkinson's disease; Primate studies

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; CARBIDOPA PLUS LEVODOPA; DOPAMINE; DOPAMINE 1 RECEPTOR; MAZINDOL; POSTSYNAPTIC RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BASAL GANGLION; CAUDATE NUCLEUS; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE BLOOD LEVEL; DOPAMINERGIC SYSTEM; DYSKINESIA; FEMALE; GLOBUS PALLIDUS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; ISOTOPE LABELING; MALE; MONKEY; NONHUMAN; ORAL DRUG ADMINISTRATION; PARKINSONISM; PRIORITY JOURNAL; TISSUE LEVEL;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; ANTIPARKINSON AGENTS; AUTORADIOGRAPHY; BRAIN MAPPING; CAUDATE NUCLEUS; CORPUS STRIATUM; DOPAMINE; FEMALE; LEVODOPA; MACACA FASCICULARIS; MALE; PARKINSON DISEASE, SECONDARY; PUTAMEN; RECEPTORS, DOPAMINE D1;

EID: 0030895023     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.870120204     Document Type: Article

References (16)

1. Hornykiewicz O. Dopamine (3-hydroxytyramine) and brain function. Pharmacol Rev 1966;18:925-964.
2. Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F. Brain dopamine and the syndromes of Parkinson and Huntington - clinical, morphological, and neurochemical correlations. J Neurol Sci 1973;20:415-455.
3. Kurlan R. International symposium on early dopamine agonist of Parkinson's disease. Arch Neurol 1988;45:204-208.
4. Wooten GF. Progress in understanding the pathophysiology of treatment-related fluctuations in Parkinson's disease. Ann Neurol 1988;24:363-365.
5. Marsden CD, Parkes JD, Quinn N. Fluctuations of disability in Parkinson's disease - clinical aspects. In: Marsden CD, Fahn S, eds. Movement disorders. London: Butterworth Scientific, 1982:96-122.
6. Barbeau A. High-level levodopa therapy in severely akinetic parkinsonian patients:, twelve years later. In: Rinne-VK, Klinger M, Stamm G, eds. Parkinson's disease: current progress, problems and management. Amsterdam: Elsevier, 1980:229-239.
7. Marsden CD, Parkes JD. Success and problems of long-term levodopa therapy in Parkinson's disease. Lancet 1977:1:345-349.
8. Kebabian JW, Calne DB. Multiple receptors for dopamine. Nature 1979;277:93-6.
9. Guttman M, Seeman P. L-DOPA reverses the elevated density ' of D2 dopamine receptors in Parkinson's disease striatum. J Neural Transm 1985;64:93-103.
10. Joyce JN, Murray A. Distribution of D1 and D2-like dopamine receptors in human brain. In: Niznik HB, ed. Dopamine receptor function and pharmacology. New York: Marcel Dekker, 1993:345-382.
11. Rinne JO, Laihinen A, Lönnberg P, Marjanäki P, Rinne UK. A post-mortem study on striatal dopamine receptors in Parkinson's disease Brain Res 1991;556:117-122.
12. Sawle GV, Brook DJ, Ibanez V, Frankowiak RSJ. Striatal D2 receptor density is inversely proportional to dopa uptake in untreated hemiparkinson's disease: a positron emission tomography study. J Neurol Neurosurg Psychiatry 1990;53:177.
13. Seeman P, Bzowej NH, Guan HC, et al. Human brain D-1 and D-2 dopamine receptors in schizophrenia, Alzheimer's, Parkinson's and Huntington's diseases. Neuropsychopharmacology 1987;1:5-15.
14. Pierot L, Desnot C, Blin J, et al. D1 and D2-type dopamine receptors in patients with Parkinson's disease and progressive palsy. J Neurol Sci 1988;86:291-306.
15. 3H]SCH 23390 labelled D-1 dopamine receptors are un changed in schizophrenia and parkinson's disease. Eur J Pharmacol 1985;114:235-237.
16. 3H]SCH 23390 to D-1 receptors in the putamen of control and parkinsonian subjects. Eur J Pharmacol. 1985;113:467-468.